Previous studies have identified a soluble form of CD36 (sCD36) in circulation as a novel biomarker for NAFLD, type 2 diabetes mellitus and atherosclerosis (Handberg et al., 2012; Liani et al., 2012; Heeboll et al., 2017). Here, CD36 is linked to metabolic dysfunction-associated steatotic liver disease.